The last couple of decades have seen a large amount of activity in the area of surrogate marker and surrogate endpoint validation, both from a clinical and a statistical perspective. Prentice1 made a pivotal contribution in the context of a single trial. Subsequently, the framework he proposed has been discussed, criticized, and extended. An important class of extensions considers several rather than a single trial. Recently, a lot of work has been done in this so-called hierarchical or meta-analytic framework. In this paper, we review both the single trial and the hierarchical framework. A number of applications, scattered throughout the literature, are brought together. We outline the statistical issues involved in trying to validate surrogate endpoints. Clearly statistical evidence should only be seen as a component in a decision making process that also involves a number of clinical and biological considerations.
Get full access to this article
View all access options for this article.
References
1.
Prentice RL.Surrogate endpoints in clinical trials: definitions and operational criteria . Statistics in Medicine1989; 8: 431-440 .
2.
Fleming TR , DeMets DL.Surrogate end points in clinical trials: are we being misled ? Annals of Internal Medicine1996; 125: 605-613 .
3.
The Cardiac Arrhythmia Suppression Trial (CAST) Investigators . Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infraction . New England Journal of Medicine1989; 321: 406-412 .
4.
DeGruttola V , Tu XM.Modelling progression of CD-4 lymphocyte count and its relationship to survival time . Biometrics1995; 50: 1003-1014 .
5.
Lagakos SW , Hoth DF.Surrogate markers in AIDS: Where are we? Where are we going ? Annals of Internal Medicine1992; 116: 599-601 .
6.
Biomarkers Definition Working Group . Biomarkers and surrogate endpoints: preferred definitions and conceptual framework . Clinical Pharmacology and Therapeutics2001; 69: 89-95 .
7.
Ferentz AE.Integrating pharmacogenomics into drug development . Pharmacogenomics2002; 3: 453-467 .
8.
Lesko LJ , Atkinson AJ.Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies . Annual Review of Pharmacololgy and Toxicology2001; 41: 347-366 .
9.
Royston P , Parmar MKB , Qian W.Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer . Statistics in Medicine2003; 22: 2239-2256 .
10.
Schatzkin A , Gail M.The promise and peril of surrogate end points in cancer research . Nature Reviews Cancer2002; 2: 19-27 .
11.
Federal Register 1998, 63, No. 179, 49583.
12.
Buyse M , Molenberghs G.Criteria for the validation of surrogate end-points in randomized experiments . Biometrics1998; 54: 1014-1029 .
13.
Molenberghs G , Geys H , Buyse M.Evaluation of surrogate end-points in randomized experiments with mixed discrete and continuous outcomes . Statistics in Medicine2001; 20: 3023-3038 .
14.
Buyse M , Molenberghs G , Burzykowski T , Renard D , Geys H.The validation of surrogate endpoints in meta-analyses of randomized experiments . Biostatistics2000; 1: 49-68 .
15.
Burzykowski T , Molenberghs G , Buyse M , Geys H , Renard D.Validation of surrogate endpoints in multiple randomized clinical trials with failure-time endpoints . Applied Statistics2001; 50: 405-422 .
16.
Renard D , Geys H , Molenberghs G , Burzykowski T , Buyse M.Validation of surrogate endpoints in multiple randomized clinical trials with discrete outcomes . Biometrical Journal2002; 44: 921-935 .
17.
Alonso A , Geys H , Molenberghs G , Vangeneugden T.Investigating the criterion validity of psychiatric symptom scales using surrogate marker validation methodology . Journal of Biopharmaceutical Statistics2002; 12: 161-178 .
18.
Renard D , Geys H , Molenberghs G , Burzykowski T , Buyse M , Vangeneugden T and Bijnens L.Validation of a longitudinally measured surrogate marker for a time-to-event endpoint . Journal of Applied Statistics2002; 30: 235-247 .
19.
Buyse M , Vangeneugden T , Bijnens L , Geys H , Renard D , Burzykowski T , Molenberghs G.Validation of Biomarkers as Surrogates for Clinical Endpoints. In Bloom JC and Dean RA , eds Biomarkers in Clinical Drug Development. Marcel Dekker: New York , 2003.
20.
Buyse M , Thirion P , Carlson RW , Burzykowski T , Molenberghs G , Piedbois P , for the Meta-Analysis Group In Cancer . Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis . Lancet2000; 356: 373-378 .
21.
Burzykowski T , Molenberghs G , Buyse M , Geys H , Renard D.The validation of surrogate endpoints using data from randomized clinical trials: a case study in advanced colorectal cancer . Journal of the Royal Statistical Society, Series A2004; 167: 103-124 .
22.
Daniels MJ , Hughes MD.Meta-analysis for the evaluation of potential surrogate markers . Statistics in Medicine1997; 16: 1515-1527 .
23.
Gail MH , Pfeiffer R , van Houwelingen HC , Carroll RJ.On meta-analytic assessment of surrogate outcomes . Biostatistics2000; 1: 231-246 .
24.
Freedman LS , Graubard BI , Schatzkin A.Statistical validation of intermediate endpoints for chronic diseases . Statistics in Medicine1992; 11: 167-178 .
25.
Choi S , Lagakos S , Schooley RT , Volberding PA.CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine . Annals of Internal Medicine1993; 118: 674-680 .
26.
Lin DY , Fleming TR , De Gruttola V.Estimating the proportion of treatment effect explained by a surrogate marker . Statistics in Medicine1997; 16: 1515-1527 .
27.
Flandre P , Saidi Y.Letter to the editor: estimating the proportion of treatment effect explained by a surrogate marker . Statistics in Medicine1999; 18: 107-115 .
28.
Begg C , Leung D.On the use of surrogate endpoints in randomized trials . Journal of the Royal Statistal Society Series A2000; 163: 26-27 .
29.
Molenberghs G , Buyse M , Geys H , Renard D , Burzykowski T.Statistical challenges in the evaluation of surrogate endpoints in randomized trials . Controlled Clinical Trials2002; 23: 607-625 .
30.
Cook RD , Weisberg S.Residuals and influence in regression. London: Chapman & Hall , 1982.
31.
Chatterjee S , Hadi AS.Sensitivity analysis in linear regression. New York: John Wiley & Sons , 1988.
32.
Clayton DG.A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence . Biometrika1978; 65: 141-151 .
33.
Hougaard P.Survival models for heterogeneous populations derived from stable distributions . Biometrika1986; 73, 387-396 .
34.
Genest C , McKay J.The joy of copulas: bivariate distributions with uniform marginals . American Statistician1986; 40, 280-283 .
35.
Shih JH , Louis, TA.Inferences on association parameter in copula models for bivariate survival data . Biometrics1995; 51, 1384-1399 .
36.
Geys H , Regan M , Catalano P , Molenberghs G.Two latent variable risk assessment approaches for combined continuous and discrete outcomes from developmental toxicity data . Journal of Agricultural, Biological, and Environmental Statistics2001; 6, 340-355 .
37.
Dale JR.Global cross ratio models for bivariate, discrete, ordered responses . Biometrics1986; 42: 909-917 .
38.
Galecki A.General class of covariance structures for two or more repeated factors in longitudinal data analysis . Communications in Statistics: Theory and Methods1994; 23: 3105-3119 .
39.
Kent, J.Information gain and a general measure of correlation . Biometrika1983, 70, 163-173 .
40.
Debruyne FJM , Murray R , Fradet Y , Johansson JE , Tyrrell C , Boccardo F , Denis L , Marberger JM , Brune D , Rassweiler J , Vangeneugden T , Bruynseels J , Janssens M , de Porre P for the Liarozole Study Group . Liarozole - a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate . Urology1998; 52: 72-81 .
41.
Sridhara R , Eisenberger MA , Sinibaldi VJ , et al.Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy . Journal of Clinical Oncology1995; 13: 2944-2953 .
42.
Smith DC , Dunn RL , Strawderman MS , et al.Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer . Journal of Clinical Oncology1998; 16: 1835-1843 .
43.
Kelly WK , Scher HI , Mazumdar M , et al.Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer . Journal of Clinical Oncology1993; 11: 607-615 .
44.
Scher HI , Kelly WK , Zhang ZF , et al.Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer . Journal of the National Cancer Institute1999; 91: 244-251 .
45.
Bubley GJ , Carducci M , Dahut W , Dawson N , Daliani D , Eisenberger M , Fidd WD , Freidlin B , Halabi S , Hudes G , Hussain M , Kaplan R , Myers C , Oh W , Petrylak DP , Reed E , Roth B , Sartor O , Scher H , Simons J , Sinibaldi V , Small EJ , Smith MR , Trump DL , Vollmer R , Wilding G.Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group . Journal of Clinical Oncology1999; 17: 3461-3467 .
46.
Buyse M , Piedbois P.On the relationship between response to treatment and survival . Statistics in Medicine1996; 15: 2797-2812 .
47.
Anderson JR , Cain KC , Gelber RD.Analysis of survival by tumor response . Journal of Clinical Oncology1983; 1: 710-719 .
48.
DeGruttola V , Wulfsohn M , Fischl MA , Tsiatis A.Modelling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex . Journal of Acquired Immune Deficiency Syndromes1993; 6: 359-365 .
49.
Diagnostic and therapeutic technology assessment (DATTA) . Surrogate markers of progressive HIV disease . Journal of the American Medical Association1992; 267: 2948-2952 .
50.
Ellenberg SS.Surrogate endpoints in clinical trials: getting closer to identifying markers for survival in AIDS . British Medical Journal1991; 302: 63-64 .
51.
Machado SG , Gail MH , Ellenberg SS.On the use of laboratory markers as surrogates for clinical endpoints in the evaluation of treatment for HIV infection . Journal of Acquired Immune Deficiency Syndromes1990; 3: 1065-1073 .
52.
Tibaldi FS , Abrahantes JC , Molenberghs G , Renard D , Burzykowski T , Buyse M , Parmar M , Stijnen T , Wolfinger R.Simplified hierarchical linear models for the evaluation of surrogate endpoints . Journal of Statistical Computation and Simulation2003; 73: 643-658 .
